These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 21061114

  • 1. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China.
    Palmer JL, Beaudet A, White J, Plun-Favreau J, Smith-Palmer J.
    Adv Ther; 2010 Nov; 27(11):814-27. PubMed ID: 21061114
    [Abstract] [Full Text] [Related]

  • 2. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
    Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ.
    Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
    [Abstract] [Full Text] [Related]

  • 3. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
    Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S.
    Curr Med Res Opin; 2005 Dec; 21(12):2063-71. PubMed ID: 16368057
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ.
    Value Health; 2009 Dec; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [Abstract] [Full Text] [Related]

  • 5. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
    Guillermin AL, Samyshkin Y, Wright D, Nguyen T, Villeneuve J.
    J Med Econ; 2011 Dec; 14(2):207-16. PubMed ID: 21361858
    [Abstract] [Full Text] [Related]

  • 6. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting.
    Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, Roze S, Foos V, Palmer AJ.
    Int J Clin Pract; 2008 Jun; 62(6):869-76. PubMed ID: 18479280
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 8. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
    Gupta V, Baabbad R, Hammerby E, Nikolajsen A, Shafie AA.
    J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
    [Abstract] [Full Text] [Related]

  • 9. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.
    Valentine WJ, Pollock RF, Plun-Favreau J, White J.
    Curr Med Res Opin; 2010 Jun; 26(6):1399-412. PubMed ID: 20387997
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting.
    Palmer JL, Knudsen MS, Aagren M, Thomsen TL.
    J Med Econ; 2010 Jun; 13(2):212-20. PubMed ID: 20350145
    [Abstract] [Full Text] [Related]

  • 11. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
    Dempsey M, Mocarski M, Langer J, Hunt B.
    J Med Econ; 2018 Nov; 21(11):1110-1118. PubMed ID: 30114954
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes.
    Luzio S, Dunseath G, Peter R, Pauvaday V, Owens DR.
    Diabetologia; 2006 Jun; 49(6):1163-8. PubMed ID: 16596358
    [Abstract] [Full Text] [Related]

  • 13. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes.
    Shafie AA, Gupta V, Baabbad R, Hammerby E, Home P.
    Diabetes Res Clin Pract; 2014 Nov; 106(2):319-27. PubMed ID: 25305133
    [Abstract] [Full Text] [Related]

  • 14. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ, Gylvin T, DeLuzio T, Raskin P.
    Endocr Pract; 2011 Nov; 17(1):41-50. PubMed ID: 20713345
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes.
    Luo Q, Zhou L, Zhou N, Hu M.
    Front Public Health; 2022 Nov; 10():1016937. PubMed ID: 36330105
    [Abstract] [Full Text] [Related]

  • 16. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ.
    J Med Econ; 2008 Nov; 11(4):651-70. PubMed ID: 19450074
    [Abstract] [Full Text] [Related]

  • 17. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
    Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M.
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):527-32. PubMed ID: 17115351
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
    Brändle M, Azoulay M, Greiner RA.
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
    [Abstract] [Full Text] [Related]

  • 19. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R.
    Clin Ther; 2005 Apr; 27 Suppl B():S75-88. PubMed ID: 16519039
    [Abstract] [Full Text] [Related]

  • 20. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
    Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer AJ.
    Adv Ther; 2007 Apr; 24(2):273-90. PubMed ID: 17565917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.